Search results for "BOC"

showing 10 items of 477 documents

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

2021

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a severe deficiency of the specific von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). ADAMTS13 deficiency is most commonly acquired due to anti-ADAMTS13 autoantibodies. It can also be inherited in the congenital form as a result of biallelic mutations in the ADAMTS13 gene. In adults, the condition is most often immune-mediated (iTTP) whereas congenital TTP (cTT…

medicine.medical_specialtyThrombotic microangiopathyTTPdiagnosisThrombotic thrombocytopenic purpuralcsh:MedicineReview030204 cardiovascular system & hematologycaplacizumabGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinefollow-upmedicinethrombotic thrombocytopenic purpuratreatmentbiologybusiness.industrylcsh:RGeneral MedicineMicroangiopathic hemolytic anemiamedicine.diseaseADAMTS13ADAMTS13biology.proteinRituximabFresh frozen plasmaCaplacizumabbusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Algoritmo diagnóstico-terapéutico de las microangiopatías trombóticas. A propósito de 2 casos

2022

Thrombotic microangiopathies (TMA) are a group of clinical syndromes associated with haemolytic anaemia, thrombocytopenia and organ dysfunction, mainly renal or neurological. They are associated with significant morbidity and mortality, so early diagnosis and treatment are essential. In this article we report two cases of TMA; a patient with thrombotic thrombocytopenic purpura (TTP) and a patient with atypical haemolytic uraemic syndrome (aHUS).

medicine.medical_specialtyThrombotic microangiopathyTherapeutic algorithmThrombotic thrombocytopenic purpura030204 cardiovascular system & hematologyurologic and male genital diseasesCritical Care and Intensive Care MedicineGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineThrombotic Microangiopathiesneoplasmsbusiness.industryOrgan dysfunction030208 emergency & critical care medicineEculizumabmedicine.diseaseADAMTS13Anesthesiology and Pain MedicineHaemolytic-uraemic syndromemedicine.symptombusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

Proliferative effect of acetylcholine on rat trachea epithelial cells is mediated by nicotinic receptors and muscarinic receptors of the M1-subtype.

2003

Acetylcholine (ACh), synthesized in mammalian non-neuronal cells such as epithelial cells of the airways, digestive tract and skin, is involved in the regulation of basic cell functions (so-called non-neuronal cholinergic system). In the present experiments rat trachea epithelial cells have been cultured to study the proliferative effect of applied ACh by [3H]thymidine incorporation. ACh (exposure time 24 h) caused a concentration-dependent increase in cell proliferation with a doubling of the [3H]thymidine incorporation at a concentration of 0.1 microM. This effect was partly reduced by 30 microM tubocurarine and completely abolished by the additional application of 1 microM atropine. The …

medicine.medical_specialtyTubocurarineMuscarinic AntagonistsNicotinic AntagonistsBiologyReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyRats Sprague-DawleyInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4AnimalsGeneral Pharmacology Toxicology and PharmaceuticsNicotinic AntagonistReceptor Muscarinic M1Muscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Epithelial CellsGeneral MedicineMolecular biologyPirenzepineReceptors MuscarinicAcetylcholineRatsTracheaAtropineEndocrinologyAcetylcholineCell Divisionmedicine.drugThymidineLife sciences
researchProduct

Thrombotic thrombocytopenic purpura (TTP) leading to pseudotumour's autoimmune pancreatitis (AIP): A case report

2012

International audience; Introduction: Autoimmune pancreatitis is an idiopathic inflammatory disease that produces pancreatic masses and ductal strictures. This benign disease can be associated with extrapancreatic manifestations including cholangitis, sialadenitis, inflammatory bowel disease or retroperitoneal fibrosis, mediastinal adenopathy, interstitial nephritis mainly due to immunoglobulin G4 (Ig G4), and occasional association with other auto-immune diseases. Observation: We report a 57-year-old woman who developed thrombotic thrombocytopenic purpura (UP) and pseudo-tumour's seronegative autoimmune pancreatitis (ATP) type 1. The patient was initially treated with pulse corticosteroids…

medicine.medical_specialtyVON-WILLEBRAND-FACTOREndocrinology Diabetes and Metabolismmedicine.medical_treatmentInterstitial nephritisAnti-Inflammatory AgentsThrombotic thrombocytopenic purpuraRetroperitoneal fibrosisGastroenterologyInflammatory bowel diseaseDISEASEAutoimmune DiseasesAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineThrombotic thrombocytopenic purpuraInternal medicine[SDV.IDA]Life Sciences [q-bio]/Food engineeringmedicineHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringSYSTEMIC-LUPUS-ERYTHEMATOSUSAutoimmune pancreatitisAutoimmune pancreatitisPurpura Thrombotic ThrombocytopenicHepatologybusiness.industryENTITYGastroenterologyMiddle Agedmedicine.diseaseSialadenitis3. Good healthPancreatitis030220 oncology & carcinogenesisImmunologyFemale030211 gastroenterology & hepatologyRituximabPlasmapheresismedicine.symptombusinessRituximabmedicine.drug
researchProduct

Patterns of changes of anti‐ADAMTS13 after plasma exchange

2006

An enzyme-linked immunosorbent assay (ELISA) has recently been developed to detect antibodies against the von Willebrand factor-cleaving protease ADAMTS13 in patients with thrombotic thrombocytopenic purpura (TTP). The ELISA is based on incubation of plasma with immobilized recombinant ADAMTS13 followed by visualization of IgG and IgM antibodies by means of secondary enzyme-labeled antibodies [1]. In a recent study, anti-ADAMTS13 IgG antibodies were detected in most patients with TTP (97%) characterized by severe ADAMTS13 deficiency (< 10% of normal) [1]. The ELISA was more sensitive than the standard inhibitor assay based upon ADAMTS13 neutralizing activity, which gave positive results in …

medicine.medical_specialtybiologybusiness.industryThrombotic thrombocytopenic purpuraAntibody titerHematologymedicine.diseaseGastroenterologyADAMTS13Immunoglobulin GTiterhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlateletAntibodybusinessIncubationJournal of Thrombosis and Haemostasis
researchProduct

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

2018

Abstract INTRODUCTION The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis. However, the identification of patient subgroups that might be at increased susceptibility of developing SC has not been systematically addressed. We report here the results of an international case-control study (MPN-K) aimed at comparing the frequency of exposure to possible causes of SC in patients with classical MPN, polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). METHODS This European Leukaemia Network (ELN) study reports MPN patients from 28 sites of 5 European countries and Israel, diagnosed in th…

medicine.medical_specialtybusiness.industryEssential thrombocythemiaPipobromanIncidence (epidemiology)ImmunologyCase-control studyCancerCell BiologyHematologymedicine.disease030226 pharmacology & pharmacyBiochemistryGastroenterology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMedicineRisk factorSkin cancerbusinessMyelofibrosismedicine.drugBlood
researchProduct

Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective

2012

Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-α and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. H…

medicine.medical_specialtybusiness.industryPublic healthHepatitis C virusRibavirinAntiviral therapymedicine.disease_causeVirologyResponse to treatmentVirusTelaprevirchemistry.chemical_compoundchemistryBoceprevirmedicineMinireviewbusinessmedicine.drugWorld Journal of Virology
researchProduct

Boceprevir in the treatment of chronic hepatitis C virus infection

2011

1Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, and National Network Center for Hepatology and Gastroenterology Research, instituto de Salud Carlos iii, CiBeReHD Spain; 2CSiSP, Center for Public Health Research, Public Health Department, Generalitat Valenciana and Microbioloy Department/ institut Cavanilles, University of Valencia, Valencia, Spain; 3National Network Center for Biomedical Research in epidemiology and Public Health, instituto de Salud Carlos iii, CiBeReSP Spain

medicine.medical_specialtybusiness.industryPublic healthImmunologyTransplantationchemistry.chemical_compoundInfectious DiseaseschemistryChronic hepatitisVirologyFamily medicineBoceprevirEpidemiologymedicinebusinessVirus Adaptation and Treatment
researchProduct

Anticoagulation in a Neurosurgical Patient with Heparin-Induced Thrombocytopenia Type II with Argatroban and Fondaparinux after Clipping of an Intrac…

2009

Background: Therapeutic anticoagulation in patients after a major neurosurgical procedure remains critical because of the risk of a major intracranial bleed. Novel drugs could play

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologyClipping (medicine)Case Report · Kasuistikmedicine.diseaseFondaparinuxArgatrobanNeurosurgical ProcedureSurgeryAneurysmNeurosurgical patientHeparin-induced thrombocytopeniamedicineImmunology and AllergyNeurosurgerybusinessmedicine.drug
researchProduct

Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy

2014

Background: This study is aimed at describing the epidemiological and economic burden that HCV will generate in the next few years in Italy. Furthermore, the impact that future anti-HCV treatments may have on the burden of disease was considered. The analysis has been developed over the period 2013-2030 from the Italian National Health Service (NHS) perspective.Methods: A published system dynamic model was adapted for Italy in order to quantify the HCV-infected population, the disease progression and the associated cost from 1950 to 2030. The model structure was based on transition probabilities reflecting the natural history of the disease. In order to estimate the efficacy of current anti…

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationTelaprevirlaw.inventionClinical trialchemistry.chemical_compoundRandomized controlled trialchemistrylawBoceprevirHealth careEmergency medicineEpidemiologymedicineOperations managementbusinesseducationHealth policymedicine.drugSSRN Electronic Journal
researchProduct